Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy

Hesketh, Paul J.; Sanz-Altamira, Pedro; Bushey, Julie A.; Hesketh, Ann M.

doi:10.1007/s00520-011-1180-2

Cited by 17 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 20 Another prospective trial found that in patients with colorectal cancer receiving FOLFOX chemotherapy, standard prophylaxis prevented 90% of CINV in the first 24 h, but after 5 days of follow-up, this value decreased to 54% due to delayed nausea and vomiting. 21 A number of studies have shown that 5-HT3 RA provides better control of CINV in the acute phase, but it is less effective in preventing CINV in the delayed phase. 22 Because of the poor control of delayed vomiting caused by MEC in the dual drug regimen, for this group of patients, we need to explore more drug combinations to better control delayed nausea and vomiting.…”

Section: Discussionmentioning

confidence: 99%

<p>Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study</p>

Tong

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose Dexamethasone combined with 5-hydroxytryptamine type 3 receptor antagonists (5-HT3 RA) dual regimen is the standard prophylaxis regimen for patients receiving moderately emetogenic chemotherapy (MEC). However, it has been found in real-world practice that chemotherapy-induced nausea and vomiting (CINV) remains poorly controlled among patients with gastrointestinal tumor, especially in those with high-risk factors for vomiting, such as female, young, and non-alcoholic individuals. Hence, we aimed to evaluate the efficacy of an olanzapine-containing triple regimen in this clinical setting. Patients and Methods We retrospectively reviewed the clinical records of gastrointestinal tumor patients who received mFOLFOX6, XELOX, or FOLFIRI chemotherapy at two institutions. All patients included were female and less than 55 years old, with no history of drinking. The patients were divided into two groups for olanzapine-containing triple therapy (olanzapine, tropisetron, and dexamethasone) and non-olanzapine dual therapy (tropisetron and dexamethasone). The study outcomes were complete response (CR), complete control (CC), nausea control, and quality of life (QoL) by the functional living index-emesis (FLIE) questionnaire. Results A total of 93 patients were included in the study (olanzapine: 40; control: 53). The CR rate in the olanzapine group was significantly higher than that in the control group in delayed and overall phase (75.0% vs 54.7%, p=0.044; 70.0% vs 47.2%; p=0.028). The CC rate in the overall phase was also better in the olanzapine group (62.5% vs 39.6%, p=0.029). The control of nausea in the overall phase showed a superior trend in the olanzapine group (p=0.059). The olanzapine group exhibited higher FLIE scores, which demonstrated better QoL. More patients in the olanzapine group exhibited somnolence and dizziness. Conversely, the incidence of insomnia and anorexia in the olanzapine group was lower. Conclusion This retrospective study indicates that in gastrointestinal tumor patients with high-risk factors for CINV who were receiving MEC, olanzapine-containing triple antiemetic regimen exhibit better efficacy and QoL as compared to non-olanzapine dual regimen. Further randomized studies are required to confirm these results.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study</p>

Tong

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…To date there have been few studies in the cancer population of the impact of telecommunication-based devices that regularly collect data from patients at home and transmit the results to a healthcare professional for response in real-time. Given the distressing and serious side-effects that are common during and following cancer treatments 2 – 21 this is surprising given the apparent cost-effectiveness of these systems in chronic disease patients. This review aimed to identify papers that not only described remote monitoring systems in cancer patients, but also statistically analyzed patient clinical and health care system outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…nausea, vomiting, mucositis, diarrhea and febrile neutropenia). 2 – 11 While some side-effects, such as fatigue and mucositis, are not in themselves life threatening, they are associated with poorer treatment compliance, impaired quality of life, and increased infections and time spent in hospital. 12 – 14 Fatigue also has a significant impact on patient quality of life and is associated with mood disturbance.…”

Section: Introductionmentioning

confidence: 99%

Benefits of remote real-time side-effect monitoring systems for patients receiving cancer treatment

Kofoed¹,

Breen²,

Gough³

et al. 2012

Oncol Rev

View full text Add to dashboard Cite

In Australia, the incidence of cancer diagnoses is rising along with an aging population. Cancer treatments, such as chemotherapy, are increasingly being provided in the ambulatory care setting. Cancer treatments are commonly associated with distressing and serious side-effects and patients often struggle to manage these themselves without specialized real-time support. Unlike chronic disease populations, few systems for the remote real-time monitoring of cancer patients have been reported. However, several prototype systems have been developed and have received favorable reports. This review aimed to identify and detail systems that reported statistical analyses of changes in patient clinical outcomes, health care system usage or health economic analyses. Five papers were identified that met these criteria. There was wide variation in the design of the monitoring systems in terms of data input method, clinician alerting and response, groups of patients targeted and clinical outcomes measured. The majority of studies had significant methodological weaknesses. These included no control group comparisons, small sample sizes, poor documentation of clinical interventions or measures of adherence to the monitoring systems. In spite of the limitations, promising results emerged in terms of improved clinical outcomes (e.g. pain, depression, fatigue). Health care system usage was assessed in two papers with inconsistent results. No studies included health economic analyses. The diversity in systems described, outcomes measured and methodological issues all limited between-study comparisons. Given the acceptability of remote monitoring and the promising outcomes from the few studies analyzing patient or health care system outcomes, future research is needed to rigorously trial these systems to enable greater patient support and safety in the ambulatory setting.

show abstract

“…The risk of delayed CINV has been studied best in chemotherapy regimens containing high-dose cisplatin or anthracyclines and cyclophosphamide (AC) combinations. However, delayed CINV is also associated with moderately emetogenic chemotherapy (non-AC MEC) regimens [ 5 – 10 ]. Non-AC MEC consists of a broad range of chemotherapeutic agents, with emetogenic potentials of 30 to 90 %; agents like oxaliplatin and irinotecan have an emetogenic potential in the lower part of this range, as opposed to carboplatin, which is at the high end [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials

Vorst

Neefjes

Konings

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

PurposeDelayed chemotherapy-induced nausea and vomiting (CINV) remains an important adverse effect of moderately emetogenic chemotherapy not containing anthracyclines and cyclophosphamide (non-AC MEC). In this review, we summarize current literature to update recommendations for delayed CINV prophylaxis after non-AC MEC.MethodsWe conducted a systematic search in PubMed and conference proceedings from ASCO, ESMO, and MASCC. Included randomized controlled trials (RCTs) aimed to prospectively evaluate the efficacy of two or more antiemetic strategies in the prevention of delayed CINV after the administration of non-AC MEC. At least one of the following endpoints was used: complete response, complete control, no nausea, no vomiting, and/or no use of rescue medication.ResultsOur search provided 247 publications. Nine met the predefined criteria. Included RCTs reported outcomes on palonosetron, aprepitant, casopitant, netupitant/palonosetron (NEPA), olanzapine, and megestrol acetate.ConclusionsSuperiority of palonosetron over first-generation 5-HT3 receptor antagonists for the prevention of acute and delayed CINV after non-AC MEC has not been proven. The addition of an NK1 receptor antagonist to first-generation 5-HT3 receptor antagonists does not significantly improve the incidence of delayed CINV after non-AC MEC. The efficacy of a single-day regimen of dexamethasone with palonosetron is non-inferior to multiday dexamethasone. NEPA, olanzapine, and megestrol acetate show highly effective complete response (CR) rates.Electronic supplementary materialThe online version of this article (doi:10.1007/s00520-015-2778-6) contains supplementary material, which is available to authorized users.

show abstract

Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy

Cited by 17 publications

References 24 publications

<p>Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study</p>

<p>Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study</p>

Benefits of remote real-time side-effect monitoring systems for patients receiving cancer treatment

Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials

Contact Info

Product

Resources

About